GeneDx Holdings Corp at Goldman Sachs Healthcare Conference Transcript
All right. Good morning, everyone. I'm Evie Koslosky, the life science tools and diagnostics analyst here at Goldman Sachs. I'm joined here today by GeneDx CFO, Kevin Feeley. Thank you so much for being here.
Yeah, thanks for having me.
Questions & Answers
GeneDx has been the market leader in rare disease diagnostics for some time, kind of beginning with expert genetics, I guess now moving into new markets where these patients can be diagnosed earlier. What prompted this shift into the nongenetic markets like pediatric neurology?
Yes. Look, I think it really starts with the problem we're trying to solve. Nearly 1 in 10 Americans has an undiagnosed rare disease, and it's a much larger patient population than I think the name rare disease gives rise to. And if you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
